PMGC Holdings (ELAB) Total Current Liabilities (2022 - 2026)
PMGC Holdings (ELAB) posted Total Current Liabilities of $11.3 million for Q1 2026, up 186.58% sequentially from $3.9 million in Q4 2025, and up 1386.02% YoY from $760268.0 in Q1 2025.
PMGC Holdings (ELAB) Total Current Liabilities (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Total Current Liabilities for 5 years, with the latest figure at $11.3 million in Q1 2026.
- Quarterly Total Current Liabilities rose 1386.02% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 1386.02% YoY) and the FY2025 annual result came in at $3.9 million, up 119.12% from the prior year.
- Total Current Liabilities advanced to $11.3 million in Q1 2026 per ELAB's latest filing, from $3.9 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $1.6 billion in Q3 2023 and troughed at $326301.0 in Q2 2025.
- A 5-year average of $139.5 million and a median of $1.9 million in 2024 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Current Liabilities plunged 99.87% in 2024, then surged 1386.02% in 2026.
- Over 5 years, Total Current Liabilities stood at $588272.0 in 2022, then surged by 120.54% to $1.3 million in 2023, then jumped by 38.68% to $1.8 million in 2024, then jumped by 119.12% to $3.9 million in 2025, then jumped by 186.58% to $11.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $11.3 million, $3.9 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 630.93 Mn |
| 10 | PMGC Holdings | 30.87 Mn | 12.08 Mn | 385,691.00 | 15.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.30 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 326,301.00 |
| Mar 31, 2025 | 760,268.00 |
| Dec 31, 2024 | 1.80 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 1.64 Bn |
| Dec 31, 2022 | 588,272.00 |